Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

142.85 +0.07 (+0.05%)
Official Closing Price Updated: 4:15 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?
Stocks inched higher during midday trading in New York on Wednesday, with the momentum carrying over from the previous day when the tech-heavy Nasdaq 100 achieved fresh record highs. 
Via Benzinga
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
MarketBeat Week in Review – 12/4 - 12/8
Stocks finished in the green to close the week; investors believe the jobs report will allow the Fed to leave interest rates unchanged when they meet next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Three Lessons For Investing In Biotech Companies
Many successful blockbusters started with a small trial. But you should temper your expectations until a larger, more rigorous trial is conducted. 
Via Talk Markets
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Biotech reversal confirmed: what's ahead for the IBB?
The recent reversal and reclaim of the significant $124 support level in the IBB holds importance, indicating a potential shift in momentum. 
Via MarketBeat
Topics ETFs
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
You Don't Have to Pick a Winner in Biotech. Here's Why.
If you invest over the long term, you'll increase your chances of victory. 
Via The Motley Fool
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
When News Moves So Fast, Stocks Can Stand Still
As far as the market goes, it feels like time is standing still. 
Via Talk Markets
Johnson & Johnson Stock: Is Now the Time to Sell?
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff 
Via InvestorPlace
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
Fresh Look At Long Bonds
As long as the S&P 500 outperforms long bonds (TLT) risk is on. 
Via Talk Markets
Topics Bonds Stocks
Exposures Debt Markets US Equities
Healthcare Playbook Revisited - Growth Plus Value
Despite concerns about rising healthcare costs and ever more expensive technology for treatment encompassing drugs, devices, and data management, still innovative medicine marches on. 
Via Talk Markets
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Technical Correction Or Return Of The Bear Market?
The QQQ chart right now has a few key aspects. 
Via Talk Markets
It’s Really All About the Retail Sector Now
Should XRT break the July calendar range low, we will once again be talking about the 80-month moving average or the 6–7-year business cycle low. 
Via Talk Markets
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
Industry ETFs In The Spotlight: Winners And Losers Of The Month Revealed
Via Benzinga
Topics ETFs
Life Science Mutual Funds Compared To ETFs And What Is In Your Portfolio?
It is important to track sectors of the market because trends to create volatility. For example the COVID pandemic created a diagnostics and vaccine revenue bubble that dissipated over several months. 
Via Talk Markets
Topics ETFs
Exposures COVID-19
BRICS And The Recent Headline
At a time when the world is experiencing de-globalization, an alliance of countries including Brazil, Russia, China, South Africa and possibly India is a potential threat to the west. 
Via Talk Markets
The US Dollar And Long Bonds Doing The Dosey Doe
With BRICS happening ahead of Jackson Hole, it would be good to look at the technical charts on both the dollar and the long bonds. 
Via Talk Markets
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotechnology On Drugs
​​​​​​​Biotechnology has traded basically sideways since the start of 2023. 
Via Talk Markets
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.